Greenwich Investment Management Cut Stake in Geo Group New (GEO) as Market Valuation Declined; As Gilead Sciences Com (GILD) Share Value Rose, Boston Common Asset Management Has Decreased Its Holding

May 17, 2018 - By Moses P. Lee

The GEO Group, Inc. (NYSE:GEO) Logo

Greenwich Investment Management Inc decreased its stake in Geo Group Inc New (GEO) by 53.04% based on its latest 2017Q4 regulatory filing with the SEC. Greenwich Investment Management Inc sold 39,247 shares as the company’s stock declined 15.61% with the market. The institutional investor held 34,746 shares of the real estate investment trusts company at the end of 2017Q4, valued at $820,000, down from 73,993 at the end of the previous reported quarter. Greenwich Investment Management Inc who had been investing in Geo Group Inc New for a number of months, seems to be less bullish one the $2.87 billion market cap company. The stock decreased 0.51% or $0.12 during the last trading session, reaching $23.51. About 476,254 shares traded. The GEO Group, Inc. (NYSE:GEO) has declined 34.79% since May 17, 2017 and is downtrending. It has underperformed by 46.34% the S&P500.

Boston Common Asset Management Llc decreased its stake in Gilead Sciences Inc Com (GILD) by 6.44% based on its latest 2017Q4 regulatory filing with the SEC. Boston Common Asset Management Llc sold 4,877 shares as the company’s stock rose 1.93% while stock markets declined. The institutional investor held 70,853 shares of the health care company at the end of 2017Q4, valued at $5.08 million, down from 75,730 at the end of the previous reported quarter. Boston Common Asset Management Llc who had been investing in Gilead Sciences Inc Com for a number of months, seems to be less bullish one the $87.66B market cap company. The stock decreased 0.20% or $0.135 during the last trading session, reaching $67.415. About 3.39M shares traded. Gilead Sciences, Inc. (NASDAQ:GILD) has risen 9.79% since May 17, 2017 and is uptrending. It has underperformed by 1.76% the S&P500.

Among 5 analysts covering The GEO Group (NYSE:GEO), 5 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. The GEO Group had 14 analyst reports since August 4, 2015 according to SRatingsIntel. The stock of The GEO Group, Inc. (NYSE:GEO) has “Buy” rating given on Tuesday, April 11 by Canaccord Genuity. Suntrust Robinson maintained The GEO Group, Inc. (NYSE:GEO) on Thursday, September 1 with “Buy” rating. The stock of The GEO Group, Inc. (NYSE:GEO) earned “Buy” rating by Canaccord Genuity on Friday, February 24. SunTrust maintained the shares of GEO in report on Thursday, September 1 with “Buy” rating. The firm has “Buy” rating by SunTrust given on Wednesday, October 18. As per Monday, December 12, the company rating was maintained by Canaccord Genuity. Canaccord Genuity maintained The GEO Group, Inc. (NYSE:GEO) on Wednesday, August 24 with “Buy” rating. The stock of The GEO Group, Inc. (NYSE:GEO) has “Buy” rating given on Friday, July 14 by J.P. Morgan. Canaccord Genuity maintained it with “Buy” rating and $3500 target in Monday, August 7 report. Canaccord Genuity maintained the stock with “Buy” rating in Friday, November 11 report.

More news for The GEO Group, Inc. (NYSE:GEO) were recently published by: Businesswire.com, which released: “The GEO Group Reports First Quarter 2018 Results” on April 26, 2018. Seekingalpha.com‘s article titled: “The GEO’s (GEO) CEO George Zoley on Q1 2018 Results – Earnings Call Transcript” and published on April 26, 2018 is yet another important article.

Analysts await The GEO Group, Inc. (NYSE:GEO) to report earnings on August, 6. They expect $0.48 earnings per share, down 21.31% or $0.13 from last year’s $0.61 per share. GEO’s profit will be $58.56 million for 12.24 P/E if the $0.48 EPS becomes a reality. After $0.57 actual earnings per share reported by The GEO Group, Inc. for the previous quarter, Wall Street now forecasts -15.79% negative EPS growth.

Greenwich Investment Management Inc, which manages about $387.59M and $69.76 million US Long portfolio, upped its stake in Triangle Cap Corp (NYSE:TCAP) by 145,116 shares to 271,484 shares, valued at $2.58 million in 2017Q4, according to the filing.

Boston Common Asset Management Llc, which manages about $24.33 billion and $843.00 million US Long portfolio, upped its stake in Disney Walt Co Com Disney (NYSE:DIS) by 2,938 shares to 86,541 shares, valued at $9.30 million in 2017Q4, according to the filing. It also increased its holding in Weyerhaeuser Co Com (NYSE:WY) by 125,069 shares in the quarter, for a total of 173,986 shares, and has risen its stake in Fifth Third Bancorp Com (NASDAQ:FITB).

Since January 2, 2018, it had 0 insider buys, and 22 sales for $44.80 million activity. 60,000 shares valued at $4.68M were sold by WILSON GAYLE E on Friday, February 9. Alton Gregg H sold 25,000 shares worth $1.97 million. 50,000 shares were sold by MARTIN JOHN C, worth $3.66M on Monday, April 2. 100,000 shares were sold by Meyers James R, worth $8.02M on Tuesday, January 16. On Wednesday, February 21 the insider Washington Robin L sold $401,566.

Analysts await Gilead Sciences, Inc. (NASDAQ:GILD) to report earnings on July, 25. They expect $1.43 EPS, down 43.03% or $1.08 from last year’s $2.51 per share. GILD’s profit will be $1.86B for 11.79 P/E if the $1.43 EPS becomes a reality. After $1.37 actual EPS reported by Gilead Sciences, Inc. for the previous quarter, Wall Street now forecasts 4.38% EPS growth.

More notable recent Gilead Sciences, Inc. (NASDAQ:GILD) news were published by: 247Wallst.com which released: “Analysts Show More Caution Toward Gilead’s Mystical Recovery” on May 02, 2018, also Seekingalpha.com with their article: “FDA OKs expanded use for Gilead’s Truvada” published on May 15, 2018, Seekingalpha.com published: “Gilead Sciences (GILD) Presents at Bank of America Merrill Lynch 2018 Healthcare Conference (Transcript)” on May 16, 2018. More interesting news about Gilead Sciences, Inc. (NASDAQ:GILD) were released by: Seekingalpha.com and their article: “Gilead Sciences: Resist Sentiment, Stop Speculating And Invest” published on May 15, 2018 as well as Seekingalpha.com‘s news article titled: “Atara Biotherapeutics: A Gift That Keeps On Giving” with publication date: May 17, 2018.

Investors sentiment decreased to 0.8 in 2017 Q4. Its down 0.23, from 1.03 in 2017Q3. It dived, as 95 investors sold GILD shares while 545 reduced holdings. 104 funds opened positions while 411 raised stakes. 972.68 million shares or 1.57% more from 957.62 million shares in 2017Q3 were reported. Dynamic Capital Mngmt stated it has 3,895 shares or 0.1% of all its holdings. Hl Fincl Svcs Ltd Liability Company accumulated 0.08% or 57,447 shares. Bryn Mawr Company has invested 0.47% of its portfolio in Gilead Sciences, Inc. (NASDAQ:GILD). Rhenman Prtnrs Asset Mgmt accumulated 285,751 shares. Cambridge Investment Advisors Inc has 0.17% invested in Gilead Sciences, Inc. (NASDAQ:GILD). Orbimed Lc, New York-based fund reported 521,600 shares. First National Co reported 0.11% stake. Carret Asset Management Ltd owns 0.07% invested in Gilead Sciences, Inc. (NASDAQ:GILD) for 6,481 shares. Alpha Windward Ltd Liability Co reported 2,805 shares or 0.12% of all its holdings. Cadence Fincl Bank Na holds 0.1% or 3,918 shares in its portfolio. Piedmont Advisors Llc owns 282,052 shares or 0.41% of their US portfolio. Money Mngmt Ltd Llc reported 2.64% of its portfolio in Gilead Sciences, Inc. (NASDAQ:GILD). Dixon Hubard Feinour Brown Va holds 0.07% or 3,704 shares in its portfolio. Azimuth Mgmt Ltd Limited Liability Company holds 0.19% or 35,837 shares. Wheatland Inc reported 1.81% stake.

Among 30 analysts covering Gilead Sciences (NASDAQ:GILD), 21 have Buy rating, 0 Sell and 9 Hold. Therefore 70% are positive. Gilead Sciences had 130 analyst reports since July 29, 2015 according to SRatingsIntel. The stock of Gilead Sciences, Inc. (NASDAQ:GILD) earned “Buy” rating by Needham on Wednesday, July 29. The stock of Gilead Sciences, Inc. (NASDAQ:GILD) has “Outperform” rating given on Wednesday, November 2 by RBC Capital Markets. The firm has “Hold” rating given on Friday, April 29 by Maxim Group. On Friday, October 2 the stock rating was downgraded by Morgan Stanley to “Equal-Weight”. The stock of Gilead Sciences, Inc. (NASDAQ:GILD) has “Hold” rating given on Tuesday, July 26 by Needham. Mizuho maintained Gilead Sciences, Inc. (NASDAQ:GILD) on Tuesday, July 25 with “Buy” rating. As per Monday, June 12, the company rating was maintained by Jefferies. The company was maintained on Wednesday, February 7 by Morgan Stanley. The firm has “Neutral” rating by Bank of America given on Wednesday, February 7. The firm has “Neutral” rating given on Wednesday, December 20 by Credit Suisse.

Gilead Sciences, Inc. (NASDAQ:GILD) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By1 Moses P. Lee

Automatic Stock Updates

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:








Recent Posts